While survival outcomes for Black women improved among all tumor subtypes when GCC was given, racial and ethnic disparities in survival outcomes persisted among patients with hormone receptor–positive/ERBB2-negative and hormone receptor–positive/ERBB2-positive subtypes. The gene discussed is ERBB2; the disease is goblet cell carcinoma.